-
Clinical Pharmacology and Therapeutics Oct 1977Bendroflumethiazide (bft), 10 mg, was administered orally to 9 healthy volunteers. The concentrations of the diuretic in plasma and urine were determined by gas-liquid...
Bendroflumethiazide (bft), 10 mg, was administered orally to 9 healthy volunteers. The concentrations of the diuretic in plasma and urine were determined by gas-liquid chromatography (GLC). Peak plasma levels (86 +/- 18 ng/ml) of bft were reached at 2 +/- 0.4 hr. The concentration declined with a mean t1/2 of 3.0 hr. The apparent volume of distribution averaged 1.48 L/kg. The major part of the drug was eliminated via nonrenal mechanisms, the nonrenal clearance being estimated to 269 +/- 77 ml/min and renal clearance to 105 +/- 24 ml/min. Urinary recovery of the thiazide averaged 30%.
Topics: Adolescent; Adult; Bendroflumethiazide; Calcium; Chromatography, Gas; Diuresis; Female; Humans; Kinetics; Magnesium; Male; Natriuresis; Potassium; Time Factors
PubMed: 902450
DOI: 10.1002/cpt1977224385 -
Medical Times May 1961
Topics: Bendroflumethiazide; Chlorothiazide
PubMed: 13740330
DOI: No ID Found -
British Journal of Clinical Pharmacology Feb 2019The aims of the current review were to compare the efficacy of monotherapy with bendroflumethiazide vs. indapamide on mortality, cardiovascular outcomes, blood pressure,... (Comparative Study)
Comparative Study
The aims of the current review were to compare the efficacy of monotherapy with bendroflumethiazide vs. indapamide on mortality, cardiovascular outcomes, blood pressure, need for intensification of treatment and treatment withdrawal. Two authors independently screened the results of a literature search, assessed the risk of bias and extracted relevant data. Randomized clinical trials of hypertensive patients of at least a 1-year duration were included. When there was disagreement, a third reviewer was consulted. Risk ratio (RR) and mean differences were used as measures of effect. Two trials comparing bendroflumethiazide against placebo, one comparing indapamide with placebo and three of short duration directly comparing indapamide and Bendroflumethiazide, were included. No statistically significant difference was found between indapamide and bendroflumethiazide for all deaths [RR 0.82; 95% confidence interval (CI) 0.57, 1.18], cardiovascular deaths (RR 0.82; 95% CI 0.55, 1.20), noncardiovascular deaths (0.81; 95% CI 0.54, 1.22), coronary events (RR 0.73; 95% CI 0.30, 1.79) or all cardiovascular events (RR 0.89; 95% CI 0.67, 1.18). Indapamide performed worse for stroke (RR 2.21; 95% CI 1.19, 4.11), even though a reduction in RR compared with placebo was observed in both groups. There was no statistically or clinically significant difference between indapamide and bendroflumethiazide in blood pressure reduction (mean absolute difference <1 mmHg). The present review highlights a lack of studies to answer the review question but also a lack of evidence of superiority of one drug over the other. Therefore, there is a clear need for new studies directly comparing the effect of these drugs on the outcomes of interest.
Topics: Bendroflumethiazide; Blood Pressure; Coronary Artery Disease; Diuretics; Humans; Hypertension; Indapamide; Randomized Controlled Trials as Topic; Stroke; Survival Analysis; Treatment Outcome
PubMed: 30312512
DOI: 10.1111/bcp.13787 -
Clinical Pharmacology and Therapeutics Nov 1980A double-blind crossover comparison was made in 18 nonedematous hypertensive subjects with glomerular filtration rates exceeding 70 ml/min/1.73 m2 of the effects of 5 mg... (Clinical Trial)
Clinical Trial
A double-blind crossover comparison was made in 18 nonedematous hypertensive subjects with glomerular filtration rates exceeding 70 ml/min/1.73 m2 of the effects of 5 mg metolazone and 5 mg bendroflumethiazide on blood pressure and metabolic parameters. After a 4-wk run-in placebo period, patients received either metolazone or bendroflumethiazide for 6 wk in a crossover fashion with an intervening washout period of 4 wk. Metolazone induced a more sustained and greater blood pressure response than bendroflumethiazide. Changes in plasma potassium, urate, bicarbonate, renin, and angiotensin II occurred during treatment with both metolazone and bendroflumethiazide; the only significant difference, however, was in changes in plasma bicarbonate. Total body potassium (TBK), measured by whole-body monitor, did not fall outside the normal range with either metolazone or bendroflumethiazide, although metolazone induced a greater reduction in TBK (6.2 gm, 5.5% of TBK) than bendroflumethiazide (1.2 gm, 1.1% of TBK, p < 0.05). Our results suggest that metolazone is a more effective antihypertensive and induces similar but greater metabolic changes than bendroflumethiazide. The results of our comparison suggest that although changes in plasma potassium and TBK are minor, they are greater with metolazone, and potassium supplements may not be necessary in nonedematous hypertensive patients with normal renal function.
Topics: Adolescent; Adult; Aged; Antihypertensive Agents; Bendroflumethiazide; Blood Pressure; Diuretics; Female; Humans; Hypertension; Male; Metolazone; Middle Aged; Potassium
PubMed: 7438679
DOI: 10.1038/clpt.1980.211 -
BMJ Case Reports May 2011A 31-year-old hypertensive woman was admitted to hospital with palpitations. Her hypertension was treated with bendroflumethiazide, which had been increased from 2.5 to...
A 31-year-old hypertensive woman was admitted to hospital with palpitations. Her hypertension was treated with bendroflumethiazide, which had been increased from 2.5 to 5 mg daily by her general practitioner about 18 months prior to her admission. She was also on ramipril 10 mg once daily. There were no abnormal findings on examination, and a 12-lead ECG showed sinus rhythm, rate 75, with Q waves in leads V1-V2. Telemetry (over 24 h) showed ventricular bigeminy when she had her typical palpitations. Her admission serum sodium and potassium concentrations were 132 and 3.4 mmol/l, respectively. Immediately prior to planned discharge the following day, she experienced paraesthesiae, weakness, confusion and seizures accompanied by 10 s asystole on the ECG monitor. Her serum sodium had fallen to 120 mmol/l and potassium to 2.3 mmol/l. Bendroflumethiazide and ramipril were discontinued and the patient was restricted to fluids of 1.5 l/24 h. She also received potassium supplements. Her serum sodium concentration rose to normal over 6 days, and she was discharged on feeling well.
Topics: Adult; Antihypertensive Agents; Bendroflumethiazide; Female; Humans; Hyponatremia
PubMed: 22696760
DOI: 10.1136/bcr.12.2010.3594 -
Journal of the American Geriatrics... Feb 1964
Topics: Ascorbic Acid; Bendroflumethiazide; Diuretics; Edema, Cardiac; Electrolytes; Feeding and Eating Disorders; Geriatrics; Heart Failure; Humans; Hypertension; Nausea; Potassium; Toxicology; Vitamin B Complex; Vomiting
PubMed: 14118830
DOI: 10.1111/j.1532-5415.1964.tb00348.x -
Clinical Drug Investigation 2006The efficacy and safety of therapy with low-dose bendroflumethiazide 1.25 mg/day or 2.5 mg/day and potassium chloride was compared with that of enalapril 10 mg/day and... (Comparative Study)
Comparative Study Randomized Controlled Trial
Efficacy and safety of 24 weeks of therapy with bendroflumethiazide 1.25 mg/day or 2.5 mg/day and potassium chloride compared with enalapril 10 mg/day and amlodipine 5 mg/day in patients with mild to moderate primary hypertension : a multicentre, randomised, open study.
BACKGROUND
The efficacy and safety of therapy with low-dose bendroflumethiazide 1.25 mg/day or 2.5 mg/day and potassium chloride was compared with that of enalapril 10 mg/day and amlodipine 5 mg/day in patients with mild to moderate primary hypertension.
STUDY DESIGN
This was a multicentre study in general practice with patients randomised in a double-blind fashion and on open-label treatment. After a washout phase that lasted 4-6 weeks, 312 patients with a diastolic blood pressure of between 100 and 115 mm Hg were randomised in a double-blind fashion to treatment with either bendroflumethiazide 1.25 mg/day and potassium chloride (n = 117), bendroflumethiazide 2.5 mg/day and potassium chloride (n = 60), amlodipine 5 mg/day (n = 61) or enalapril 10 mg/day (n = 60), all given once daily (numbers in parentheses indicate the intention-to-treat population, with a total of 298 patients). The primary efficacy parameter was the reduction in diastolic blood pressure. Effects on systolic blood pressure, heart rate, biochemical variables, adverse events and quality of life were studied as secondary efficacy parameters.
RESULTS
All treatments reduced diastolic blood pressure significantly; reductions were as follows: 6.8 mm Hg with bendroflumethiazide 1.25 mg/day, 9.1 mm Hg with bendroflumethiazide 2.5 mg/day, 10.8 mm Hg with amlodipine 5 mg/day and 6.8 mm Hg with enalapril 10 mg/day. The reduction in diastolic blood pressure on amlodipine was significantly greater than on bendroflumethiazide 1.25 mg/day and enalapril 10 mg/day (p = 0.013). The percentage of patients achieving a diastolic blood pressure of < 95 mm Hg was 34% (SD 4.4) with bendroflumethiazide 1.25 mg/day, 48% (SD 6.5) with bendroflumethiazide 2.5 mg/day (p = 0.075 vs bendroflumethiazide 1.25 mg/day), 57% (SD 6.3) with amlodipine 5 mg/day (p = 0.004 vs bendroflumethiazide 1.25 mg/day) and 41% (SD 6.4) with enalapril 10 mg/day (p = 0.41 vs bendroflumethiazide 1.25 mg/day) [mean reductions]. The effect on systolic blood pressure was similar with all treatments. No clinically significant changes occurred in heart rate, serum potassium, blood glucose, serum urate or serum cholesterol levels. The incidences of adverse events were similar in the low-dose bendroflumethiazide groups, with significantly higher incidences in the enalapril and amlodipine groups. Quality of life was similar in the different treatment groups, but the study had limited power to detect any difference in this parameter.
CONCLUSION
The present study has confirmed, in a general practice population, that low-dose bendroflumethiazide (bendroflumethiazide 1.25-2.5 mg/day) in combination with potassium chloride is a well tolerated and efficacious first-line treatment for patients with mild to moderate essential hypertension.
Topics: Adult; Aged; Amlodipine; Bendroflumethiazide; Enalapril; Female; Humans; Hypertension; Male; Middle Aged; Potassium Chloride
PubMed: 17163239
DOI: 10.2165/00044011-200626020-00004 -
Postgraduate Medical Journal Sep 1997
Topics: Antihypertensive Agents; Bendroflumethiazide; Candy; Female; Glycyrrhiza; Humans; Hypokalemia; Middle Aged; Muscular Diseases; Plants, Medicinal
PubMed: 9373608
DOI: 10.1136/pgmj.73.863.593 -
Lancet (London, England) Mar 1982
Topics: Adolescent; Bendroflumethiazide; Epilepsy, Tonic-Clonic; Female; Humans; Suicide, Attempted
PubMed: 6120416
DOI: 10.1016/s0140-6736(82)92072-4 -
Journal of the American Geriatrics... Aug 1962
Topics: Bendroflumethiazide; Chlorothiazide; Geriatrics
PubMed: 13880590
DOI: 10.1111/j.1532-5415.1962.tb00166.x